Search

Your search keyword '"Chiaki Hosoda"' showing total 32 results
Start Over Author "Chiaki Hosoda"
32 results on '"Chiaki Hosoda"'

1. The whole blood transcriptional regulation landscape in 465 COVID-19 infected samples from Japan COVID-19 Task Force

Author

Qingbo S. Wang, Ryuya Edahiro, Ho Namkoong, Takanori Hasegawa, Yuya Shirai, Kyuto Sonehara, Hiromu Tanaka, Ho Lee, Ryunosuke Saiki, Takayoshi Hyugaji, Eigo Shimizu, Kotoe Katayama, Masahiro Kanai, Tatsuhiko Naito, Noah Sasa, Kenichi Yamamoto, Yasuhiro Kato, Takayoshi Morita, Kazuhisa Takahashi, Norihiro Harada, Toshio Naito, Makoto Hiki, Yasushi Matsushita, Haruhi Takagi, Masako Ichikawa, Ai Nakamura, Sonoko Harada, Yuuki Sandhu, Hiroki Kabata, Katsunori Masaki, Hirofumi Kamata, Shinnosuke Ikemura, Shotaro Chubachi, Satoshi Okamori, Hideki Terai, Atsuho Morita, Takanori Asakura, Junichi Sasaki, Hiroshi Morisaki, Yoshifumi Uwamino, Kosaku Nanki, Sho Uchida, Shunsuke Uno, Tomoyasu Nishimura, Takashri Ishiguro, Taisuke Isono, Shun Shibata, Yuma Matsui, Chiaki Hosoda, Kenji Takano, Takashi Nishida, Yoichi Kobayashi, Yotaro Takaku, Noboru Takayanagi, Soichiro Ueda, Ai Tada, Masayoshi Miyawaki, Masaomi Yamamoto, Eriko Yoshida, Reina Hayashi, Tomoki Nagasaka, Sawako Arai, Yutaro Kaneko, Kana Sasaki, Etsuko Tagaya, Masatoshi Kawana, Ken Arimura, Kunihiko Takahashi, Tatsuhiko Anzai, Satoshi Ito, Akifumi Endo, Yuji Uchimura, Yasunari Miyazaki, Takayuki Honda, Tomoya Tateishi, Shuji Tohda, Naoya Ichimura, Kazunari Sonobe, Chihiro Tani Sassa, Jun Nakajima, Yasushi Nakano, Yukiko Nakajima, Ryusuke Anan, Ryosuke Arai, Yuko Kurihara, Yuko Harada, Kazumi Nishio, Tetsuya Ueda, Masanori Azuma, Ryuichi Saito, Toshikatsu Sado, Yoshimune Miyazaki, Ryuichi Sato, Yuki Haruta, Tadao Nagasaki, Yoshinori Yasui, Yoshinori Hasegawa, Yoshikazu Mutoh, Tomoki Kimura, Tomonori Sato, Reoto Takei, Satoshi Hagimoto, Yoichiro Noguchi, Yasuhiko Yamano, Hajime Sasano, Sho Ota, Yasushi Nakamori, Kazuhisa Yoshiya, Fukuki Saito, Tomoyuki Yoshihara, Daiki Wada, Hiromu Iwamura, Syuji Kanayama, Shuhei Maruyama, Takashi Yoshiyama, Ken Ohta, Hiroyuki Kokuto, Hideo Ogata, Yoshiaki Tanaka, Kenichi Arakawa, Masafumi Shimoda, Takeshi Osawa, Hiroki Tateno, Isano Hase, Shuichi Yoshida, Shoji Suzuki, Miki Kawada, Hirohisa Horinouchi, Fumitake Saito, Keiko Mitamura, Masao Hagihara, Junichi Ochi, Tomoyuki Uchida, Rie Baba, Daisuke Arai, Takayuki Ogura, Hidenori Takahashi, Shigehiro Hagiwara, Genta Nagao, Shunichiro Konishi, Ichiro Nakachi, Koji Murakami, Mitsuhiro Yamada, Hisatoshi Sugiura, Hirohito Sano, Shuichiro Matsumoto, Nozomu Kimura, Yoshinao Ono, Hiroaki Baba, Yusuke Suzuki, Sohei Nakayama, Keita Masuzawa, Shinichi Namba, Takayuki Shiroyama, Yoshimi Noda, Takayuki Niitsu, Yuichi Adachi, Takatoshi Enomoto, Saori Amiya, Reina Hara, Yuta Yamaguchi, Teruaki Murakami, Tomoki Kuge, Kinnosuke Matsumoto, Yuji Yamamoto, Makoto Yamamoto, Midori Yoneda, Kazunori Tomono, Kazuto Kato, Haruhiko Hirata, Yoshito Takeda, Hidefumi Koh, Tadashi Manabe, Yohei Funatsu, Fumimaro Ito, Takahiro Fukui, Keisuke Shinozuka, Sumiko Kohashi, Masatoshi Miyazaki, Tomohisa Shoko, Mitsuaki Kojima, Tomohiro Adachi, Motonao Ishikawa, Kenichiro Takahashi, Takashi Inoue, Toshiyuki Hirano, Keigo Kobayashi, Hatsuyo Takaoka, Kazuyoshi Watanabe, Naoki Miyazawa, Yasuhiro Kimura, Reiko Sado, Hideyasu Sugimoto, Akane Kamiya, Naota Kuwahara, Akiko Fujiwara, Tomohiro Matsunaga, Yoko Sato, Takenori Okada, Yoshihiro Hirai, Hidetoshi Kawashima, Atsuya Narita, Kazuki Niwa, Yoshiyuki Sekikawa, Koichi Nishi, Masaru Nishitsuji, Mayuko Tani, Junya Suzuki, Hiroki Nakatsumi, Takashi Ogura, Hideya Kitamura, Eri Hagiwara, Kota Murohashi, Hiroko Okabayashi, Takao Mochimaru, Shigenari Nukaga, Ryosuke Satomi, Yoshitaka Oyamada, Nobuaki Mori, Tomoya Baba, Yasutaka Fukui, Mitsuru Odate, Shuko Mashimo, Yasushi Makino, Kazuma Yagi, Mizuha Hashiguchi, Junko Kagyo, Tetsuya Shiomi, Satoshi Fuke, Hiroshi Saito, Tomoya Tsuchida, Shigeki Fujitani, Mumon Takita, Daiki Morikawa, Toru Yoshida, Takehiro Izumo, Minoru Inomata, Naoyuki Kuse, Nobuyasu Awano, Mari Tone, Akihiro Ito, Yoshihiko Nakamura, Kota Hoshino, Junichi Maruyama, Hiroyasu Ishikura, Tohru Takata, Toshio Odani, Masaru Amishima, Takeshi Hattori, Yasuo Shichinohe, Takashi Kagaya, Toshiyuki Kita, Kazuhide Ohta, Satoru Sakagami, Kiyoshi Koshida, Kentaro Hayashi, Tetsuo Shimizu, Yutaka Kozu, Hisato Hiranuma, Yasuhiro Gon, Namiki Izumi, Kaoru Nagata, Ken Ueda, Reiko Taki, Satoko Hanada, Kodai Kawamura, Kazuya Ichikado, Kenta Nishiyama, Hiroyuki Muranaka, Kazunori Nakamura, Naozumi Hashimoto, Keiko Wakahara, Sakamoto Koji, Norihito Omote, Akira Ando, Nobuhiro Kodama, Yasunari Kaneyama, Shunsuke Maeda, Takashige Kuraki, Takemasa Matsumoto, Koutaro Yokote, Taka-Aki Nakada, Ryuzo Abe, Taku Oshima, Tadanaga Shimada, Masahiro Harada, Takeshi Takahashi, Hiroshi Ono, Toshihiro Sakurai, Takayuki Shibusawa, Yoshifumi Kimizuka, Akihiko Kawana, Tomoya Sano, Chie Watanabe, Ryohei Suematsu, Hisako Sageshima, Ayumi Yoshifuji, Kazuto Ito, Saeko Takahashi, Kota Ishioka, Morio Nakamura, Makoto Masuda, Aya Wakabayashi, Hiroki Watanabe, Suguru Ueda, Masanori Nishikawa, Yusuke Chihara, Mayumi Takeuchi, Keisuke Onoi, Jun Shinozuka, Atsushi Sueyoshi, Yoji Nagasaki, Masaki Okamoto, Sayoko Ishihara, Masatoshi Shimo, Yoshihisa Tokunaga, Yu Kusaka, Takehiko Ohba, Susumu Isogai, Aki Ogawa, Takuya Inoue, Satoru Fukuyama, Yoshihiro Eriguchi, Akiko Yonekawa, Keiko Kan-o, Koichiro Matsumoto, Kensuke Kanaoka, Shoichi Ihara, Kiyoshi Komuta, Yoshiaki Inoue, Shigeru Chiba, Kunihiro Yamagata, Yuji Hiramatsu, Hirayasu Kai, Koichiro Asano, Tsuyoshi Oguma, Yoko Ito, Satoru Hashimoto, Masaki Yamasaki, Yu Kasamatsu, Yuko Komase, Naoya Hida, Takahiro Tsuburai, Baku Oyama, Minoru Takada, Hidenori Kanda, Yuichiro Kitagawa, Tetsuya Fukuta, Takahito Miyake, Shozo Yoshida, Shinji Ogura, Shinji Abe, Yuta Kono, Yuki Togashi, Hiroyuki Takoi, Ryota Kikuchi, Shinichi Ogawa, Tomouki Ogata, Shoichiro Ishihara, Arihiko Kanehiro, Shinji Ozaki, Yasuko Fuchimoto, Sae Wada, Nobukazu Fujimoto, Kei Nishiyama, Mariko Terashima, Satoru Beppu, Kosuke Yoshida, Osamu Narumoto, Hideaki Nagai, Nobuharu Ooshima, Mitsuru Motegi, Akira Umeda, Kazuya Miyagawa, Hisato Shimada, Mayu Endo, Yoshiyuki Ohira, Masafumi Watanabe, Sumito Inoue, Akira Igarashi, Masamichi Sato, Hironori Sagara, Akihiko Tanaka, Shin Ohta, Tomoyuki Kimura, Yoko Shibata, Yoshinori Tanino, Takefumi Nikaido, Hiroyuki Minemura, Yuki Sato, Yuichiro Yamada, Takuya Hashino, Masato Shinoki, Hajime Iwagoe, Hiroshi Takahashi, Kazuhiko Fujii, Hiroto Kishi, Masayuki Kanai, Tomonori Imamura, Tatsuya Yamashita, Masakiyo Yatomi, Toshitaka Maeno, Shinichi Hayashi, Mai Takahashi, Mizuki Kuramochi, Isamu Kamimaki, Yoshiteru Tominaga, Tomoo Ishii, Mitsuyoshi Utsugi, Akihiro Ono, Toru Tanaka, Takeru Kashiwada, Kazue Fujita, Yoshinobu Saito, Masahiro Seike, Hiroko Watanabe, Hiroto Matsuse, Norio Kodaka, Chihiro Nakano, Takeshi Oshio, Takatomo Hirouchi, Shohei Makino, Moritoki Egi, Yosuke Omae, Yasuhito Nannya, Takafumi Ueno, Tomomi Takano, Kazuhiko Katayama, Masumi Ai, Atsushi Kumanogoh, Toshiro Sato, Naoki Hasegawa, Katsushi Tokunaga, Makoto Ishii, Ryuji Koike, Yuko Kitagawa, Akinori Kimura, Seiya Imoto, Satoru Miyano, Seishi Ogawa, Takanori Kanai, Koichi Fukunaga, and Yukinori Okada

Subjects
Science
Abstract

Genetic mechanisms influencing COVID-19 susceptibility are not well understood. Here, the authors analyzed whole blood RNA-seq data of 465 Japanese individuals with COVID-19, highlighting thousands of fine-mapped variants affecting expression and splicing of genes, as well as the presence of COVID-19 severity-interaction eQTLs.

Published
2022
Full Text
View/download PDF

2. A retrospective analysis of pembrolizumab plus chemotherapy versus pembrolizumab monotherapy for advanced or recurrent non‐small cell lung cancer

Author

Taisuke Isono, Naho Kagiyama, Shun Shibata, Hitomi Nakajima, Yuma Matsui, Kenji Takano, Takashi Nishida, Chiaki Hosoda, Eriko Kawate, Yoichi Kobayashi, Takashi Ishiguro, Yotaro Takaku, Kazuyoshi Kurashima, Tsutomu Yanagisawa, and Noboru Takayanagi

Subjects
adverse event, combination therapy, immune checkpoint inhibitor, overall survival, treatment discontinuation, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Abstract Background Although clinical trials have investigated the addition of pembrolizumab to chemotherapy for non‐small cell lung cancer, none have investigated the addition of chemotherapy to pembrolizumab. Methods We conducted a retrospective study of 71 NSCLC patients including 33 treated with pembrolizumab plus chemotherapy (combination therapy group) and 38 treated with pembrolizumab monotherapy (monotherapy group) from 1 May 2016 to 31 August 2020. Results Eleven of 33 (33.3%) patients in the combination therapy group and 37 of 38 (97.4%) patients in the monotherapy group had programmed cell death ligand‐1 (PD‐L1) tumor proportion score (TPS) ≥50%. Objective response rate (ORR) and median overall survival (OS) were not significantly different between the combination therapy group and monotherapy group (54.5% vs. 47.4, p = 0.637 and 16.6 vs. 27.0 months, p = 0.463). In patients with PD‐L1 TPS ≥50%, ORR and median OS were not different between the combination therapy group and the monotherapy group (63.6% vs. 48.6%, p = 0.499 and not reached vs. 27.0 months, p = 0.976). Thirty‐three (100%) patients experienced adverse events (AEs) in the combination therapy group and 32 (84.2%) in the monotherapy group. Treatment discontinuation at 1 year due to AEs occurred more frequently in the combination therapy group (45.2%) than in the monotherapy group (21.1%). Conclusion There was no significant difference in ORR and OS between the two groups, and treatment discontinuation was more frequent in the combination group. A randomized controlled trial is needed to evaluate the addition of chemotherapy to pembrolizumab for first‐line treatment in patients with PD‐L1 TPS ≥50%.

Published
2021
Full Text
View/download PDF

3. Pulmonary alveolar proteinosis developing during steroid treatment in a patient with organizing pneumonia in association with atypical chronic myeloid leukemia

Author

Chiaki Hosoda, Keisuke Saito, Shota Fujimoto, Yumie Yamanaka, Naoaki Watanabe, Hanae Miyagawa, Yusuke Kurita, Yoshitaka Seki, Akira Kinoshita, Yasuhiko Endo, and Kazuyoshi Kuwano

Subjects
chronic myeloid leukemia, corticosteroid therapy, organizing pneumonia, pulmonary alveolar proteinosis, Medicine, Medicine (General), R5-920
Abstract

Key Clinical Message Organizing pneumonia (OP) and pulmonary alveolar proteinosis (PAP) are rare complications in patients with hematologic disorders. We herein report a case of PAP that developed during steroid treatment for OP in a patient with atypical chronic myeloid leukemia. Physicians should pay close attention to these complications in patients with hematologic malignancies.

Published
2019
Full Text
View/download PDF

4. Characteristics of pulmonary cryptococcosis in patients with rheumatoid arthritis

Author

Ryuji Uozumi, Noboru Takayanagi, Takashi Ishiguro, Miyuki Ueda, Chiaki Hosoda, and Naomi Takata

Subjects
Medicine, Diseases of the respiratory system, RC705-779
Abstract

Background and objective A high frequency of infections complicating rheumatoid arthritis (RA) has been reported due to the immunomodulatory effect of RA or to agents with immunosuppressive effects used in its treatment. We aimed to assess clinical and radiological characteristics of pulmonary cryptococcosis in patients with and without RA.Methods We retrospectively reviewed the medical records of 52 patients with pulmonary cryptococcosis and divided them into two groups, those with RA and without RA, and compared clinical characteristics and radiological findings between them.Results Eleven (21.2%) of the 52 patients had RA. Median follow-up periods were 51.2 (range: 1.1–258.7) months for patients with RA and 19.1 (range: 0.63–246.9) months for patients without RA. Among the patients with RA, 81.8% were women, with a mean age of 68.1 years. Female sex and respiratory comorbidities were significantly more frequent in patients with RA than in patients without RA. Frequencies of concomitant cryptococcal meningitis and respiratory failure were not different between the groups. There were no significant differences in frequency of any radiological findings, locations and number between the two groups. Among patients with RA, all but one responded well to antifungal treatment. During the antifungal treatment course, one (9.1%) patient with RA died of cryptococcosis. Despite continuing antirheumatic drugs, no patients had recurrence of pulmonary cryptococcosis during follow-up.Conclusion Other than some differences in background, there were no clinical, radiological or prognostic differences between the patients with and without RA with pulmonary cryptococcosis. The administration of antirheumatic therapy had no negative effect on the clinical course of antifungal treatment.

Published
2021
Full Text
View/download PDF

5. Clinical course and findings of 14 patients with COVID-19 compared with 5 patients with conventional human coronavirus pneumonia

Author

Takashi Ishiguro, Kenji Takano, Naho Kagiyama, Chiaki Hosoda, Yoichi Kobayashi, Yotaro Takaku, Naomi Takata, Miyuki Ueda, Yasuhiro Morimoto, Keisuke Kasuga, Ryota Ozawa, Taisuke Isono, Takashi Nishida, Eriko Kawate, Yasuhito Kobayashi, Yoshihiko Shimizu, Kazuyoshi Kurashima, Tsutomu Yanagisawa, and Noboru Takayanagi

Subjects
COVID-19, Novel coronavirus 2019, Pneumonia, SARS-CoV-2, Wuhan, Diseases of the respiratory system, RC705-779
Abstract

Objective: To clarify what future problems must be resolved and how clinical findings of SARS-CoV-2 infection differ from those of cHCoV infection. Methods: Patients and Methods Clinical characteristics of 14 patients with laboratory-confirmed Coronavirus disease 2019 (COVID-19) and 5 patients with cHCoV pneumonia admitted to our institution and treated up to March 8, 2020, were retrospectively analyzed. Results: On admission, 10 patients had pneumonia, 5 of whom had pulmonary shadows detectable only via computed tomography (CT). During hospitalization, another patient with no pulmonary shadows on admission developed pneumonia. In total, 11 (78.6%) of the 14 patients developed pneumonia, indicating its high prevalence in COVID-19. During hospitalization, the patients' symptoms spontaneously relapsed and resolved, and gastrointestinal symptoms were frequently found. C-reactive protein values showed correlation with the patients’ clinical courses. Ritonavir/lopinavir were administered to 5 patients whose respiratory conditions worsened during admission, all of whom improved. However, the pneumonia in the 6 other patients improved without antivirals. None of the 14 patients died, whereas 5 other patients with cHCoV pneumonia were in respiratory failure on admission, and one patient (20%) died. Conclusion: Both SARS-CoV-2 and cHCoV can cause severe pneumonia. Problems for future resolution include whether antiviral agents administered in cases of mild or moderate severity can reduce the number of severe cases, and whether antivirals administered in severe cases can reduce mortality.

Published
2020
Full Text
View/download PDF

6. Spontaneous regression of primary endobronchial extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue

Author

Chiaki Hosoda, Takashi Ishiguro, Nobumasa Takahashi, Nobufumi Kamiishi, Yoshihiko Shimizu, and Noboru Takayanagi

Subjects
Diseases of the respiratory system, RC705-779
Abstract

Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) of pulmonary origin is a relatively rare disease. In particular, reports of MALT lymphoma occurring and localized in the trachea or bronchus have been limited. Pulmonary MALT lymphoma has been reported to demonstrate spontaneous regression, whereas there is only one reported case of spontaneous regression of primary endobronchial MALT lymphoma. We herein report the case of a 70-year-old man with primary endobronchial MALT lymphoma who showed spontaneous regression with an interest of endobronchial findings. Keywords: Endobronchial extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue, Spontaneous regression, Bronchus

Published
2019
Full Text
View/download PDF

7. Outcomes of EGFR tyrosine kinase inhibitors and immune checkpoint inhibitors for advanced EGFR-mutated non-small cell lung cancer

Author

Taisuke Isono, Jiro Hasemi, Airi Hasegawa, Takashi Nishida, Chiaki Hosoda, Eriko Kawate, Yoichi Kobayashi, Takashi Ishiguro, Naho Kagiyama, Kazuyoshi Kurashima, Tsutomu Yanagisawa, and Noboru Takayanagi

Abstract

Purpose No clinical trial has compared osimertinib with afatinib. We reviewed clinical data of patients with epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) to identify predictive factors for clinical outcome of first-line EGFR tyrosine kinase inhibitors (TKIs), efficacy and safety of several EGFR-TKIs, and efficacy of immune checkpoint inhibitors (ICIs). Methods We retrospectively studied 170 patients with EGFR-mutated NSCLC who received first-line EGFR-TKIs from January 1, 2011 to March 31, 2021. Results Programmed cell death ligand-1 (PD-L1) tumor proportion score (TPS) was available in 66 patients, of whom 14, 25, and 27 had PD-L1 TPS ≥50%, 1-49%, and Conclusion Osimertinib was more effective and less frequently caused severe adverse events. Patients treated with ICIs had better prognosis.

Published
2022
Full Text
View/download PDF

8. Author response for 'Clinical significance of pre‐diabetes, undiagnosed diabetes, and diagnosed diabetes on clinical outcomes in COVID‐19: Integrative analysis from the Japan COVID‐19 Task Force'

Author

null Takahiro Fukushima, null Shotaro Chubachi, null Ho Namkoong, null Takanori Asakura, null Hiromu Tanaka, null Ho Lee, null Shuhei Azekawa, null Yukinori Okada, null Ryuji Koike, null Akinori Kimura, null Seiya Imoto, null Satoru Miyano, null Seishi Ogawa, null Takanori Kanai, null Koichi Fukunaga, null Shiro Otake, null Kensuke Nakagawara, null Atsuho Morita, null Mayuko Watase, null Kaori Sakurai, null Takuya Kusumoto, null Katsunori Masaki, null Hiroki Kabata, null Hirofumi Kamata, null Makoto Ishii, null Naoki Hasegawa, null Kazuhisa Takahashi, null Norihiro Harada, null Toshio Naito, null Makoto Hiki, null Yasushi Matsushita, null Haruhi Takagi, null Ryousuke Aoki, null Ai Nakamura, null Sonoko Harada, null Hitoshi Sasano, null Shinnosuke Ikemura, null Satoshi Okamori, null Hideki Terai, null Junichi Sasaki, null Hiroshi Morisaki, null Yoshifumi Uwamino, null Kosaku Nanki, null Yohei Mikami, null Sho Uchida, null Shunsuke Uno, null Rino Ishihara, null Yuta Matsubara, null Tomoyasu Nishimura, null Takunori Ogawa, null Toshiro Sato, null Tetsuya Ueda, null Masanori Azuma, null Ryuichi Saito, null Toshikatsu Sado, null Yoshimune Miyazaki, null Ryuichi Sato, null Yuki Haruta, null Tadao Nagasaki, null Yoshinori Yasui, null Yoshinori Hasegawa, null Soichiro Ueda, null Ai Tada, null Masayoshi Miyawaki, null Masaomi Yamamoto, null Eriko Yoshida, null Reina Hayashi, null Tomoki Nagasaka, null Sawako Arai, null Yutaro Kaneko, null Kana Sasaki, null Takashi Ishiguro, null Taisuke Isono, null Shun Shibata, null Yuma Matsui, null Chiaki Hosoda, null Kenji Takano, null Takashi Nishida, null Yoichi Kobayashi, null Yotaro Takaku, null Noboru Takayanagi, null Etsuko Tagaya, null Masatoshi Kawana, null Ken Arimura, null Yasushi Nakamori, null Kazuhisa Yoshiya, null Fukuki Saito, null Tomoyuki Yoshihara, null Daiki Wada, null Hiromu Iwamura, null Syuji Kanayama, null Shuhei Maruyama, null Takanori Hasegawa, null Kunihiko Takahashi, null Tatsuhiko Anzai, null Satoshi Ito, null Akifumi Endo, null Yuji Uchimura, null Yasunari Miyazaki, null Takayuki Honda, null Tomoya Tateishi, null Shuji Tohda, null Naoya Ichimura, null Kazunari Sonobe, null Chihiro Tani Sassa, null Jun Nakajima, null Masumi Ai, null Takashi Yoshiyama, null Ken Ohta, null Hiroyuki Kokuto, null Hideo Ogata, null Yoshiaki Tanaka, null Kenichi Arakawa, null Masafumi Shimoda, null Takeshi Osawa, null Yasushi Nakano, null Yukiko Nakajima, null Ryusuke Anan, null Ryosuke Arai, null Yuko Kurihara, null Yuko Harada, null Kazumi Nishio, null Yoshikazu Mutoh, null Tomonori Sato, null Reoto Takei, null Satoshi Hagimoto, null Yoichiro Noguchi, null Yasuhiko Yamano, null Hajime Sasano, null Sho Ota, null Yusuke Suzuki, null Sohei Nakayama, null Keita Masuzawa, null Tomomi Takano, null Kazuhiko Katayama, null Koji Murakami, null Mitsuhiro Yamada, null Hisatoshi Sugiura, null Hirohito Sano, null Shuichiro Matsumoto, null Nozomu Kimura, null Yoshinao Ono, null Hiroaki Baba, null Rie Baba, null Daisuke Arai, null Takayuki Ogura, null Hidenori Takahashi, null Shigehiro Hagiwara, null Genta Nagao, null Shunichiro Konishi, null Ichiro Nakachi, null Hiroki Tateno, null Isano Hase, null Shuichi Yoshida, null Shoji Suzuki, null Miki Kawada, null Hirohisa Horinouchi, null Fumitake Saito, null Keiko Mitamura, null Masao Hagihara, null Junichi Ochi, null Tomoyuki Uchida, null Ryuya Edahiro, null Yuya Shirai, null Kyuto Sonehara, null Tatsuhiko Naito, null Kenichi Yamamoto, null Shinichi Namba, null Ken Suzuki, null Takayuki Shiroyama, null Yuichi Maeda, null Takuro Nii, null Yoshimi Noda, null Takayuki Niitsu, null Yuichi Adachi, null Takatoshi Enomoto, null Saori Amiya, null Reina Hara, null Toshihiro Kishikawa, null Shuhei Yamada, null Shuhei Kawabata, null Noriyuki Kijima, null Masatoshi Takagaki, null Noa Sasa, null Yuya Ueno, null Motoyuki Suzuki, null Norihiko Takemoto, null Hirotaka Eguchi, null Takahito Fukusumi, null Takao Imai, null Munehisa Fukushima, null Haruhiko Kishima, null Hidenori Inohara, null Kazunori Tomono, null Kazuto Kato, null Haruhiko Hirata, null Yoshito Takeda, null Atsushi Kumanogoh, null Naoki Miyazawa, null Yasuhiro Kimura, null Reiko Sado, null Hideyasu Sugimoto, null Akane Kamiya, null Naota Kuwahara, null Akiko Fujiwara, null Tomohiro Matsunaga, null Yoko Sato, null Takenori Okada, null Takashi Inoue, null Toshiyuki Hirano, null Keigo Kobayashi, null Hatsuyo Takaoka, null Koichi Nishi, null Masaru Nishitsuji, null Mayuko Tani, null Junya Suzuki, null Hiroki Nakatsumi, null Hidefumi Koh, null Tadashi Manabe, null Yohei Funatsu, null Fumimaro Ito, null Takahiro Fukui, null Keisuke Shinozuka, null Sumiko Kohashi, null Masatoshi Miyazaki, null Tomohisa Shoko, null Mitsuaki Kojima, null Tomohiro Adachi, null Motonao Ishikawa, null Kenichiro Takahashi, null Kazuyoshi Watanabe, null Yoshihiro Hirai, null Hidetoshi Kawashima, null Atsuya Narita, null Kazuki Niwa, null Yoshiyuki Sekikawa, null Hisako Sageshima, null Yoshihiko Nakamura, null Kota Hoshino, null Junichi Maruyama, null Hiroyasu Ishikura, null Tohru Takata, null Takashi Ogura, null Hideya Kitamura, null Eri Hagiwara, null Kota Murohashi, null Hiroko Okabayashi, null Takao Mochimaru, null Shigenari Nukaga, null Ryosuke Satomi Yoshitaka Oyamada, null Nobuaki Mori, null Tomoya Baba, null Yasutaka Fukui, null Mitsuru Odate, null Shuko Mashimo, null Yasushi Makino, null Kazuma Yagi, null Mizuha Hashiguchi, null Junko Kagyo, null Tetsuya Shiomi, null Kodai Kawamura, null Kazuya Ichikado, null Kenta Nishiyama, null Hiroyuki Muranaka, null Kazunori Nakamura, null Satoshi Fuke, null Hiroshi Saito, null Tomoya Tsuchida, null Shigeki Fujitani, null Mumon Takita, null Daiki Morikawa, null Toru Yoshida, null Takehiro Izumo, null Minoru Inomata, null Naoyuki Kuse, null Nobuyasu Awano, null Mari Tone, null Akihiro Ito, null Toshio Odani, null Masaru Amishima, null Takeshi Hattori, null Yasuo Shichinohe, null Takashi Kagaya, null Toshiyuki Kita, null Kazuhide Ohta, null Satoru Sakagami, null Kiyoshi Koshida, null Morio Nakamura, null Koutaro Yokote, null Taka‐Aki Nakada, null Ryuzo Abe, null Taku Oshima, null Tadanaga Shimada, null Kentaro Hayashi, null Tetsuo Shimizu, null Yutaka Kozu, null Hisato Hiranuma, null Yasuhiro Gon, null Namiki Izumi, null Kaoru Nagata, null Ken Ueda, null Reiko Taki, null Satoko Hanada, null Naozumi Hashimoto, null Keiko Wakahara, null Koji Sakamoto, null Norihito Omote, null Akira Ando, null Yu Kusaka, null Takehiko Ohba, null Susumu Isogai, null Aki Ogawa, null Takuya Inoue, null Nobuhiro Kodama, null Yasunari Kaneyama, null Shunsuke Maeda, null Takashige Kuraki, null Takemasa Matsumoto, null Masahiro Harada, null Takeshi Takahashi, null Hiroshi Ono, null Toshihiro Sakurai, null Takayuki Shibusawa, null Yusuke Kawamura, null Akiyoshi Nakayama, null Hirotaka Matsuo, null Yoshifumi Kimizuka, null Akihiko Kawana, null Tomoya Sano, null Chie Watanabe, null Ryohei Suematsu, null Makoto Masuda, null Aya Wakabayashi, null Hiroki Watanabe, null Suguru Ueda, null Masanori Nishikawa Ayumi Yoshifuji, null Kazuto Ito, null Saeko Takahashi, null Kota Ishioka, null Yusuke Chihara, null Mayumi Takeuchi, null Keisuke Onoi, null Jun Shinozuka, null Atsushi Sueyoshi, null Yoji Nagasaki, null Masaki Okamoto, null Sayoko Ishihara, null Masatoshi Shimo, null Yoshihisa Tokunaga, null Masafumi Watanabe, null Sumito Inoue, null Akira Igarashi, null Masamichi Sato, null Nobuyuki Hizawa, null Yoshiaki Inoue, null Shigeru Chiba, null Kunihiro Yamagata, null Yuji Hiramatsu, null Hirayasu Kai, null Satoru Fukuyama, null Yoshihiro Eriguchi, null Akiko Yonekawa, null Keiko Kano, null Koichiro Matsumoto, null Kensuke Kanaoka, null Shoichi Ihara, null Kiyoshi Komuta, null Koichiro Asano, null Tsuyoshi Oguma, null Yoko Ito, null Satoru Hashimoto, null Masaki Yamasaki, null Yu Kasamatsu, null Yuko Komase, null Naoya Hida, null Takahiro Tsuburai, null Baku Oyama, null Yuichiro Kitagawa, null Tetsuya Fukuta, null Takahito Miyake, null Shozo Yoshida, null Shinji Ogura, null Minoru Takada, null Hidenori Kanda, null Shinji Abe, null Yuta Kono, null Yuki Togashi, null Hiroyuki Takoi, null Ryota Kikuchi, null Shinichi Ogawa, null Tomouki Ogata, null Shoichiro Ishihara, null Arihiko Kanehiro, null Shinji Ozaki, null Yasuko Fuchimoto, null Sae Wada, null Nobukazu Fujimoto, null Kei Nishiyama, null Mariko Terashima, null Satoru Beppu, null Kosuke Yoshida, null Osamu Narumoto, null Hideaki Nagai, null Nobuharu Ooshima, null Mitsuru Motegi, null Akira Umeda, null Kazuya Miyagawa, null Hisato Shimada, null Mayu Endo, null Yoshiyuki Ohira, null Hironori Sagara, null Akihiko Tanaka, null Shin Ohta, null Tomoyuki Kimura, null Yoko Shibata, null Yoshinori Tanino, null Takefumi Nikaido, null Hiroyuki Minemura, null Yuki Sato, null Yuichiro Yamada, null Takuya Hashino, null Masato Shinoki, null Hajime Iwagoe, null Hiroshi Takahashi, null Kazuhiko Fujii, null Hiroto Kishi, null Tomoo Ishii, null Masayuki Kanai, null Tomonori Imamura, null Tatsuya Yamashita, null Masakiyo Yatomi, null Toshitaka Maeno, null Shinichi Hayashi, null Mai Takahashi, null Mizuki Kuramochi, null Isamu Kamimaki, null Yoshiteru Tominaga, null Mitsuyoshi Utsugi, null Akihiro Ono, null Toru Tanaka, null Takeru Kashiwada, null Kazue Fujita, null Yoshinobu Saito, null Masahiro Seike, null Masahiro Kanai, null Ryunosuke Saiki, null Takayoshi Hyugaji, null Eigo Shimizu, null Kotoe Katayama, null Satoru Miyawaki, null Meiko Takahashi, null Fumihiko Matsuda, null Yosuke Omae, null Yasuhito Nannya, null Takafumi Ueno, null Yuko Kitagawa, null Katsushi Tokunaga, and null The Japan COVID‐19 Task Force

Published
2022
Full Text
View/download PDF

9. Rheumatoid Arthritis Accompanying Diffuse Panbronchiolitis

Author

Yoshinori Kawabata, Taisuke Isono, Noboru Takayanagi, Chiaki Hosoda, Yuma Matsui, Yoshihiko Shimizu, and Shun Shibata

Subjects
rheumatoid arthritis, medicine.medical_specialty, Haemophilus Infections, Case Report, Lung biopsy, 030204 cardiovascular system & hematology, surgical lung biopsy, Arthritis, Rheumatoid, 03 medical and health sciences, 0302 clinical medicine, Clarithromycin, Internal Medicine, Medicine, Humans, Lung, Bronchiectasis, business.industry, Chronic sinusitis, General Medicine, Middle Aged, medicine.disease, Dermatology, Bronchiolitis, Rheumatoid arthritis, diffuse panbronchiolitis, Japanese, Sputum, 030211 gastroenterology & hepatology, Female, medicine.symptom, business, Diffuse panbronchiolitis, medicine.drug
Abstract

A 58-year-old woman with rheumatoid arthritis (RA) visited our hospital complaining of a persistent cough and sputum for the past year. She had a high cold hemagglutinin titer and chronic sinusitis. Chest computed tomography revealed bilateral diffuse centrilobular nodules, bronchiectasis, and bronchial wall thickening. A surgical lung biopsy was performed that confirmed diffuse panbronchiolitis (DPB) because of the lymphocytic and plasmacytic infiltrates in the respiratory bronchioles. Her condition improved after the administration of clarithromycin. Several cases of RA complicating DPB have previously been reported, but only in Japan [please check this carefully]. We need to consider DPB as a bronchiolitis types accompanying RA among Japanese patients.

Published
2021

10. Outcome and risk factor of immune‐related adverse events and pneumonitis in patients with advanced or postoperative recurrent non‐small cell lung cancer treated with immune checkpoint inhibitors

Author

Tsutomu Yanagisawa, Naho Kagiyama, Kazuyoshi Kurashima, Kenji Takano, Takashi Nishida, Eriko Kawate, Taisuke Isono, Yoichi Kobayashi, Youtaro Takaku, Noboru Takayanagi, Chiaki Hosoda, and Takashi Ishiguro

Subjects
Adult, Male, 0301 basic medicine, Pulmonary and Respiratory Medicine, Oncology, medicine.medical_specialty, Lung Neoplasms, Drug-Related Side Effects and Adverse Reactions, Immune checkpoint inhibitor, Pembrolizumab, 03 medical and health sciences, 0302 clinical medicine, Risk Factors, Atezolizumab, Carcinoma, Non-Small-Cell Lung, Internal medicine, medicine, Humans, Risk factor, Lung cancer, Adverse effect, Immune Checkpoint Inhibitors, Idiopathic interstitial pneumonia, Aged, Retrospective Studies, Pneumonitis, Aged, 80 and over, business.industry, pneumonitis, Pneumonia, Original Articles, General Medicine, Middle Aged, Prognosis, medicine.disease, lung cancer, 030104 developmental biology, 030220 oncology & carcinogenesis, Female, Original Article, Nivolumab, business, immune‐related adverse event
Abstract

Background Non‐small cell lung cancer (NSCLC) patients with pre‐existing respiratory diseases have been excluded in clinical trials of immune checkpoint inhibitor (ICI) therapy, and it is unknown whether the same degree of response can be expected as that in patients without pre‐existing respiratory diseases and if they are associated with increased risk for various immune‐related adverse events (irAEs) and ICI pneumonitis. This study aimed to evaluate predictive factors of clinical response, prognostic factors, risk factors of irAEs, and ICI pneumonitis in NSCLC patients with or without pre‐existing respiratory diseases. Methods We conducted a retrospective study of 180 NSCLC patients who received ICI monotherapy of nivolumab, pembrolizumab, or atezolizumab from 1 January 2016 to 31 March 2019. Results A total of 119 patients had pre‐existing respiratory diseases, including 20 with pre‐existing idiopathic interstitial pneumonias (IIPs). A total of 85 patients experienced irAEs, of which ICI pneumonitis was the most frequent adverse event, occurring in 27 patients. Of the three patients who died from irAEs, all from ICI pneumonitis, two had pulmonary emphysema and one had pre‐existing IIP. In multivariate analyses, irAEs were associated with objective response rate (ORR) and favorable OS, and IIPs were associated with increased risk for ICI pneumonitis. However, IIPs were not associated with low ORR or poor OS. Conclusions Pre‐existing IIPs were a risk factor for ICI pneumonitis. However, this study showed that ICI therapy can be offered to patients with pre‐existing respiratory diseases with the expectation of the same degree of response as that in patients without pre‐existing respiratory diseases. Key points Significant findings of the study: Pre‐existing IIPs were a risk factor for ICI pneumonitis, but objective response rate and prognosis of patients with IIPs were similar to those of other patients. What this study adds: In patients with pre‐existing IIPs, ICI pneumonitis should be noted. However, ICI therapy can be offered to patients with pre‐existing respiratory diseases with the expectation of the same degree of response as that in patients without pre‐existing respiratory diseases, Pre‐existing IIPs were a risk factor for ICI pneumonitis. Objective response rate and prognosis of patients with IIPs were similar to those of other patients.

Published
2020
Full Text
View/download PDF

11. Antibody Response as Assessed by A Rapid Immunochromatographic Assay in Patients with COVID-19 Pneumonia Caused by the Novel Coronavirus, SARS-CoV-2

Author

Yotaro Takaku, Tsuyoshi Numano, Taisuke Isono, Mayumi Koike, Takashi Ishiguro, Yoichi Kobayashi, Kenji Takano, Eriko Kawate, Naho Kagiyama, Takashi Nishida, Tsutomu Yanagisawa, Chiaki Hosoda, Kazuyoshi Kurashima, and Susumu Yokota

Subjects
medicine.medical_specialty, Coronavirus disease 2019 (COVID-19), biology, business.industry, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), General Medicine, medicine.disease, Gastroenterology, Virus, Pneumonia, Antibody response, Internal medicine, biology.protein, Medicine, In patient, Severe acute respiratory syndrome coronavirus, Antibody, business
Abstract

An immunochromatographic assay that has been developed for the detection of antibodies in blood-derived specimens is raising expectations for the diagnosis of COVID-19, the disease caused by the novel corona virus SARS-CoV-2 Herein, we studied the interval from symptom onset to the first positive results of the immunochromatographic assay for IgM and IgG antibodies in 52 patients with a definitive diagnosis of COVID-19 (disease confirmed by the PCR test) Furthermore, we also examined the test results in 35 patients with acute fever and pneumonia who were negative by the PCR test All patients with a definitive diagnosis of COVID-19 were confirmed to be antibody-positive The mean time from symptom onset to the first positive result for IgM antibody was 11 9 days (minimum: 5, median: 11), and that to the first positive result for IgG antibody was 11 2 days (minimum: 5, median: 11) No significant difference was observed between the tests for IgM and IgG antibodies in terms of the percentage of positive patients or the interval from first onset to the first positive test result There were no patients in whom the test for IgM became positive before the test for IgG In 45 patients (87%), both IgM and IgG became positive at the same time, and in the remaining 7 patients (13%), the test for IgG became positive before that for IgM Of 35 patients with acute fever and pneumonia who tested negative by the PCR test for SARS-CoV-2, not COVID-19, 6 (17 1%) and 1 (2 8%) showed positive results for anti-IgG antibody and anti-IgM antibody, respectively Our study results were quite limited, and we do not intend to conduct a performance evaluation of the reagents contained in the detection kits Assessment of antibody detection reagents for the immunochromatographic assay, which can be used as a complementary test to PCR, is expected in the future;however, the findings should be reviewed carefully

Published
2020
Full Text
View/download PDF

12. Predictors of Severe COVID-19 Pneumonia

Author

Takashi Ishiguro, Kazuyoshi Kurashima, Noboru Takayanagi, Chiaki Hosoda, Yasuhiro Morimoto, Youichi Kobayashi, Keisuke Kasuga, Eriko Kawate, Naho Kagiyama, Takashi Nishida, Kenji Takano, Yotaro Takaku, Tsutomu Yanagisawa, Ryouta Ozawa, and Taisuke Isono

Subjects
medicine.medical_specialty, Multivariate analysis, Coronavirus disease 2019 (COVID-19), medicine.drug_class, business.industry, Lymphocyte, General Medicine, Disease, medicine.disease, Gastroenterology, respiratory tract diseases, Hypoxemia, Diarrhea, medicine.anatomical_structure, Viral pneumonia, Internal medicine, medicine, Antiviral drug, medicine.symptom, business
Abstract

In patients with COVID-19, age over 50 years is also considered as an indication for antiviral drug therapy, in addition to hypoxemia At this time, it still remains unclear as to which clinical markers can be considered as being predictive of severe COVID-19 pneumonia with hypoxemia We categorized 49 patients with COVID-19 pneumonia into the following 4 groups by the clinical manifestations: stage A: no symptoms, and no viral pneumonia on chest computed tomography (CT);stage B: symptom (s) present, but no viral pneumonia on CT;stage C: viral pneumonia on CT, but no hypoxemia;stage D: viral pneumonia on CT, with hypoxemia The clinical background characteristics that were correlated with the disease severity were the patient age, presence/absence of complications, smoking history, and presence/absence of fever and diarrhea, but multivariate analysis identified only smoking history as being significantly predictive of stage D disease The lymphocyte count, serum CRP level, serum ferritin level and incidence of consolidation on CT were significantly different between patients with stage C and stage D disease Therefore, we propose five predictors of severe COVID-19 pneumonia, namely, smoking history, lymphocyte count 1,200 μL, serum ferritin 400 ng/mL, serum CRP 2 5 mg/dL, and presence of consolidation on CT The interval (in days) from the onset of symptom (s) to the first negative result of PCR for SARS-CoV2 was well correlated with the number of these risk factors in each patient (p�E�E 0001�E�E

Published
2020
Full Text
View/download PDF

13. A case of invasive pulmonary aspergillosis diagnosed by transbronchial lung biopsy during treatment for diabetic ketoacidosis in a type 1 diabetic patient

Author

Yumie Yamanaka, Ayu Kiritani, Chiaki Hosoda, Yoshitaka Seki, Kazuyoshi Kuwano, Naoaki Watanabe, Shota Fujimoto, Keisuke Saito, Ikumi Fujisaki, Hiroshi Takeda, Yasuhiko Endo, Akira Kinoshita, and Hanae Miyagawa

Subjects
0301 basic medicine, Microbiology (medical), medicine.medical_specialty, Diabetic ketoacidosis, Combination therapy, 030106 microbiology, Malignancy, 03 medical and health sciences, 0302 clinical medicine, Bronchoscopy, Internal medicine, medicine, Pharmacology (medical), 030212 general & internal medicine, skin and connective tissue diseases, Voriconazole, Type 1 diabetes, medicine.diagnostic_test, business.industry, Micafungin, Cancer, bacterial infections and mycoses, medicine.disease, respiratory tract diseases, Infectious Diseases, business, medicine.drug
Abstract

Invasive pulmonary aspergillosis (IPA) patients with non-hematological malignancy are far less than with hematological malignancy patients. We encountered a very rare case of IPA in which type 1 diabetes was the only conceivable risk factor. Further, according to the diagnostic categories of the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) criteria for IPA, the frequency of proven diagnosis is very low. Here we report a proven IPA, which rapidly developed when the patient with type 1 diabetes was being treated for diabetic ketoacidosis, which was successfully treated with the combination therapy of voriconazole (VRCZ) and micafungin (MCFG), based on early diagnosis using bronchoscopy.

Published
2020
Full Text
View/download PDF

14. The whole blood transcriptional regulation landscape in 465 COVID-19 infected samples from Japan COVID-19 Task Force

Author

Qingbo S. Wang, Ryuya Edahiro, Ho Namkoong, Takanori Hasegawa, Yuya Shirai, Kyuto Sonehara, Hiromu Tanaka, Ho Lee, Ryunosuke Saiki, Takayoshi Hyugaji, Eigo Shimizu, Kotoe Katayama, Masahiro Kanai, Tatsuhiko Naito, Noah Sasa, Kenichi Yamamoto, Yasuhiro Kato, Takayoshi Morita, Kazuhisa Takahashi, Norihiro Harada, Toshio Naito, Makoto Hiki, Yasushi Matsushita, Haruhi Takagi, Masako Ichikawa, Ai Nakamura, Sonoko Harada, Yuuki Sandhu, Hiroki Kabata, Katsunori Masaki, Hirofumi Kamata, Shinnosuke Ikemura, Shotaro Chubachi, Satoshi Okamori, Hideki Terai, Atsuho Morita, Takanori Asakura, Junichi Sasaki, Hiroshi Morisaki, Yoshifumi Uwamino, Kosaku Nanki, Sho Uchida, Shunsuke Uno, Tomoyasu Nishimura, Takashri Ishiguro, Taisuke Isono, Shun Shibata, Yuma Matsui, Chiaki Hosoda, Kenji Takano, Takashi Nishida, Yoichi Kobayashi, Yotaro Takaku, Noboru Takayanagi, Soichiro Ueda, Ai Tada, Masayoshi Miyawaki, Masaomi Yamamoto, Eriko Yoshida, Reina Hayashi, Tomoki Nagasaka, Sawako Arai, Yutaro Kaneko, Kana Sasaki, Etsuko Tagaya, Masatoshi Kawana, Ken Arimura, Kunihiko Takahashi, Tatsuhiko Anzai, Satoshi Ito, Akifumi Endo, Yuji Uchimura, Yasunari Miyazaki, Takayuki Honda, Tomoya Tateishi, Shuji Tohda, Naoya Ichimura, Kazunari Sonobe, Chihiro Tani Sassa, Jun Nakajima, Yasushi Nakano, Yukiko Nakajima, Ryusuke Anan, Ryosuke Arai, Yuko Kurihara, Yuko Harada, Kazumi Nishio, Tetsuya Ueda, Masanori Azuma, Ryuichi Saito, Toshikatsu Sado, Yoshimune Miyazaki, Ryuichi Sato, Yuki Haruta, Tadao Nagasaki, Yoshinori Yasui, Yoshinori Hasegawa, Yoshikazu Mutoh, Tomoki Kimura, Tomonori Sato, Reoto Takei, Satoshi Hagimoto, Yoichiro Noguchi, Yasuhiko Yamano, Hajime Sasano, Sho Ota, Yasushi Nakamori, Kazuhisa Yoshiya, Fukuki Saito, Tomoyuki Yoshihara, Daiki Wada, Hiromu Iwamura, Syuji Kanayama, Shuhei Maruyama, Takashi Yoshiyama, Ken Ohta, Hiroyuki Kokuto, Hideo Ogata, Yoshiaki Tanaka, Kenichi Arakawa, Masafumi Shimoda, Takeshi Osawa, Hiroki Tateno, Isano Hase, Shuichi Yoshida, Shoji Suzuki, Miki Kawada, Hirohisa Horinouchi, Fumitake Saito, Keiko Mitamura, Masao Hagihara, Junichi Ochi, Tomoyuki Uchida, Rie Baba, Daisuke Arai, Takayuki Ogura, Hidenori Takahashi, Shigehiro Hagiwara, Genta Nagao, Shunichiro Konishi, Ichiro Nakachi, Koji Murakami, Mitsuhiro Yamada, Hisatoshi Sugiura, Hirohito Sano, Shuichiro Matsumoto, Nozomu Kimura, Yoshinao Ono, Hiroaki Baba, Yusuke Suzuki, Sohei Nakayama, Keita Masuzawa, Shinichi Namba, Takayuki Shiroyama, Yoshimi Noda, Takayuki Niitsu, Yuichi Adachi, Takatoshi Enomoto, Saori Amiya, Reina Hara, Yuta Yamaguchi, Teruaki Murakami, Tomoki Kuge, Kinnosuke Matsumoto, Yuji Yamamoto, Makoto Yamamoto, Midori Yoneda, Kazunori Tomono, Kazuto Kato, Haruhiko Hirata, Yoshito Takeda, Hidefumi Koh, Tadashi Manabe, Yohei Funatsu, Fumimaro Ito, Takahiro Fukui, Keisuke Shinozuka, Sumiko Kohashi, Masatoshi Miyazaki, Tomohisa Shoko, Mitsuaki Kojima, Tomohiro Adachi, Motonao Ishikawa, Kenichiro Takahashi, Takashi Inoue, Toshiyuki Hirano, Keigo Kobayashi, Hatsuyo Takaoka, Kazuyoshi Watanabe, Naoki Miyazawa, Yasuhiro Kimura, Reiko Sado, Hideyasu Sugimoto, Akane Kamiya, Naota Kuwahara, Akiko Fujiwara, Tomohiro Matsunaga, Yoko Sato, Takenori Okada, Yoshihiro Hirai, Hidetoshi Kawashima, Atsuya Narita, Kazuki Niwa, Yoshiyuki Sekikawa, Koichi Nishi, Masaru Nishitsuji, Mayuko Tani, Junya Suzuki, Hiroki Nakatsumi, Takashi Ogura, Hideya Kitamura, Eri Hagiwara, Kota Murohashi, Hiroko Okabayashi, Takao Mochimaru, Shigenari Nukaga, Ryosuke Satomi, Yoshitaka Oyamada, Nobuaki Mori, Tomoya Baba, Yasutaka Fukui, Mitsuru Odate, Shuko Mashimo, Yasushi Makino, Kazuma Yagi, Mizuha Hashiguchi, Junko Kagyo, Tetsuya Shiomi, Satoshi Fuke, Hiroshi Saito, Tomoya Tsuchida, Shigeki Fujitani, Mumon Takita, Daiki Morikawa, Toru Yoshida, Takehiro Izumo, Minoru Inomata, Naoyuki Kuse, Nobuyasu Awano, Mari Tone, Akihiro Ito, Yoshihiko Nakamura, Kota Hoshino, Junichi Maruyama, Hiroyasu Ishikura, Tohru Takata, Toshio Odani, Masaru Amishima, Takeshi Hattori, Yasuo Shichinohe, Takashi Kagaya, Toshiyuki Kita, Kazuhide Ohta, Satoru Sakagami, Kiyoshi Koshida, Kentaro Hayashi, Tetsuo Shimizu, Yutaka Kozu, Hisato Hiranuma, Yasuhiro Gon, Namiki Izumi, Kaoru Nagata, Ken Ueda, Reiko Taki, Satoko Hanada, Kodai Kawamura, Kazuya Ichikado, Kenta Nishiyama, Hiroyuki Muranaka, Kazunori Nakamura, Naozumi Hashimoto, Keiko Wakahara, Sakamoto Koji, Norihito Omote, Akira Ando, Nobuhiro Kodama, Yasunari Kaneyama, Shunsuke Maeda, Takashige Kuraki, Takemasa Matsumoto, Koutaro Yokote, Taka-Aki Nakada, Ryuzo Abe, Taku Oshima, Tadanaga Shimada, Masahiro Harada, Takeshi Takahashi, Hiroshi Ono, Toshihiro Sakurai, Takayuki Shibusawa, Yoshifumi Kimizuka, Akihiko Kawana, Tomoya Sano, Chie Watanabe, Ryohei Suematsu, Hisako Sageshima, Ayumi Yoshifuji, Kazuto Ito, Saeko Takahashi, Kota Ishioka, Morio Nakamura, Makoto Masuda, Aya Wakabayashi, Hiroki Watanabe, Suguru Ueda, Masanori Nishikawa, Yusuke Chihara, Mayumi Takeuchi, Keisuke Onoi, Jun Shinozuka, Atsushi Sueyoshi, Yoji Nagasaki, Masaki Okamoto, Sayoko Ishihara, Masatoshi Shimo, Yoshihisa Tokunaga, Yu Kusaka, Takehiko Ohba, Susumu Isogai, Aki Ogawa, Takuya Inoue, Satoru Fukuyama, Yoshihiro Eriguchi, Akiko Yonekawa, Keiko Kan-o, Koichiro Matsumoto, Kensuke Kanaoka, Shoichi Ihara, Kiyoshi Komuta, Yoshiaki Inoue, Shigeru Chiba, Kunihiro Yamagata, Yuji Hiramatsu, Hirayasu Kai, Koichiro Asano, Tsuyoshi Oguma, Yoko Ito, Satoru Hashimoto, Masaki Yamasaki, Yu Kasamatsu, Yuko Komase, Naoya Hida, Takahiro Tsuburai, Baku Oyama, Minoru Takada, Hidenori Kanda, Yuichiro Kitagawa, Tetsuya Fukuta, Takahito Miyake, Shozo Yoshida, Shinji Ogura, Shinji Abe, Yuta Kono, Yuki Togashi, Hiroyuki Takoi, Ryota Kikuchi, Shinichi Ogawa, Tomouki Ogata, Shoichiro Ishihara, Arihiko Kanehiro, Shinji Ozaki, Yasuko Fuchimoto, Sae Wada, Nobukazu Fujimoto, Kei Nishiyama, Mariko Terashima, Satoru Beppu, Kosuke Yoshida, Osamu Narumoto, Hideaki Nagai, Nobuharu Ooshima, Mitsuru Motegi, Akira Umeda, Kazuya Miyagawa, Hisato Shimada, Mayu Endo, Yoshiyuki Ohira, Masafumi Watanabe, Sumito Inoue, Akira Igarashi, Masamichi Sato, Hironori Sagara, Akihiko Tanaka, Shin Ohta, Tomoyuki Kimura, Yoko Shibata, Yoshinori Tanino, Takefumi Nikaido, Hiroyuki Minemura, Yuki Sato, Yuichiro Yamada, Takuya Hashino, Masato Shinoki, Hajime Iwagoe, Hiroshi Takahashi, Kazuhiko Fujii, Hiroto Kishi, Masayuki Kanai, Tomonori Imamura, Tatsuya Yamashita, Masakiyo Yatomi, Toshitaka Maeno, Shinichi Hayashi, Mai Takahashi, Mizuki Kuramochi, Isamu Kamimaki, Yoshiteru Tominaga, Tomoo Ishii, Mitsuyoshi Utsugi, Akihiro Ono, Toru Tanaka, Takeru Kashiwada, Kazue Fujita, Yoshinobu Saito, Masahiro Seike, Hiroko Watanabe, Hiroto Matsuse, Norio Kodaka, Chihiro Nakano, Takeshi Oshio, Takatomo Hirouchi, Shohei Makino, Moritoki Egi, Yosuke Omae, Yasuhito Nannya, Takafumi Ueno, Tomomi Takano, Kazuhiko Katayama, Masumi Ai, Atsushi Kumanogoh, Toshiro Sato, Naoki Hasegawa, Katsushi Tokunaga, Makoto Ishii, Ryuji Koike, Yuko Kitagawa, Akinori Kimura, Seiya Imoto, Satoru Miyano, Seishi Ogawa, Takanori Kanai, Koichi Fukunaga, and Yukinori Okada

Subjects
Multidisciplinary, Membrane Glycoproteins, Quantitative Trait Loci, General Physics and Astronomy, COVID-19, General Chemistry, Polymorphism, Single Nucleotide, General Biochemistry, Genetics and Molecular Biology, Japan, Viral infection, Humans, Lectins, C-Type, Gene expression, Receptors, Immunologic, Transcriptomics, Genome-Wide Association Study
Abstract

Coronavirus disease 2019 (COVID-19) is a recently-emerged infectious disease that has caused millions of deaths, where comprehensive understanding of disease mechanisms is still unestablished. In particular, studies of gene expression dynamics and regulation landscape in COVID-19 infected individuals are limited. Here, we report on a thorough analysis of whole blood RNA-seq data from 465 genotyped samples from the Japan COVID-19 Task Force, including 359 severe and 106 non-severe COVID-19 cases. We discover 1169 putative causal expression quantitative trait loci (eQTLs) including 34 possible colocalizations with biobank fine-mapping results of hematopoietic traits in a Japanese population, 1549 putative causal splice QTLs (sQTLs; e.g. two independent sQTLs at TOR1AIP1), as well as biologically interpretable trans-eQTL examples (e.g., REST and STING1), all fine-mapped at single variant resolution. We perform differential gene expression analysis to elucidate 198 genes with increased expression in severe COVID-19 cases and enriched for innate immune-related functions. Finally, we evaluate the limited but non-zero effect of COVID-19 phenotype on eQTL discovery, and highlight the presence of COVID-19 severity-interaction eQTLs (ieQTLs; e.g., CLEC4C and MYBL2). Our study provides a comprehensive catalog of whole blood regulatory variants in Japanese, as well as a reference for transcriptional landscapes in response to COVID-19 infection., 「コロナ制圧タスクフォース」COVID-19患者由来の血液細胞における遺伝子発現の網羅的解析 --重症度に応じた遺伝子発現の変化には、ヒトゲノム配列の個人差が影響する--. 京都大学プレスリリース. 2022-08-23.

Published
2021

15. Frequency and Significance of Coinfection in Patients with COVID-19 at Hospital Admission

Author

Yoshihiko Shimizu, Yukari Uemura, Takashi Nishida, Yosuke Shimizu, Kenji Takano, Noboru Takayanagi, Chiaki Hosoda, Taisuke Isono, Takashi Ishiguro, Yotaro Takaku, Yasuhito Kobayashi, and Yoichi Kobayashi

Subjects
medicine.medical_specialty, medicine.medical_treatment, Pneumonia, Viral, viral pneumonia, medicine.disease_cause, Logistic regression, Internal medicine, Oxygen therapy, Internal Medicine, medicine, Humans, Retrospective Studies, business.industry, Coinfection, SARS-CoV-2, Bacterial pneumonia, COVID-19, General Medicine, medicine.disease, Hospitals, Community-Acquired Infections, Pneumonia, Viral pneumonia, Breathing, severe, prognosis, Original Article, business, Nasal cannula
Abstract

Objective Viral pneumonia is not rare in community-acquired pneumonia (CAP). Mixed or secondary pneumonia (coinfection) can be seen in viral pneumonia; however, its frequency in coronavirus disease 2019 (COVID-19) has only been investigated in a few studies of short duration, and its significance has not been fully elucidated. We investigated the frequency and significance of co-infection in patients with COVID-19 over a 1-year study period. Methods Coinfection was investigated via multiplex polymerase chain reaction (PCR), culture of respiratory samples, rapid diagnostic tests, and paired sera. We used logistic regression analysis to analyze the effect of coinfection on severity at admission and Cox proportional-hazards model analysis to analyze the effect of coinfection on need for high-flow nasal cannula, invasive mandatory ventilation use, and death, respectively. Patients We retrospectively investigated 298 patients who suffered CAP due to severe acute respiratory syndrome coronavirus-2 infection diagnosed by PCR and were admitted to our institution from February 2020 to January 2021. Results Primary viral pneumonia, and mixed viral and bacterial pneumonia, accounted for 90.3% and 9.7%, respectively, of COVID-19-associated CAP, with viral coinfection found in 30.5% of patients with primary viral pneumonia. Influenza virus was the most common (9.4%). Multivariable analysis showed coinfection not to be an independent factor of severity on admission, need for high-flow nasal cannula or invasive mandatory ventilation, and mortality. Conclusion Viral coinfection was common in COVID-19-associated CAP. Severity on admission, need for high-flow oxygen therapy or invasive mandatory ventilation, and mortality were not affected by coinfection.

Published
2021

16. Characteristics of pulmonary cryptococcosis in patients with rheumatoid arthritis

Author

Noboru Takayanagi, Chiaki Hosoda, Takashi Ishiguro, Ryuji Uozumi, Naomi Takata, and Miyuki Ueda

Subjects
0301 basic medicine, Pulmonary and Respiratory Medicine, medicine.medical_specialty, 030106 microbiology, Respiratory Infection, Arthritis, Rheumatoid, 03 medical and health sciences, Diseases of the respiratory system, 0302 clinical medicine, Internal medicine, Medicine, Humans, 030212 general & internal medicine, Respiratory system, Aged, Retrospective Studies, Lung Diseases, Fungal, RC705-779, business.industry, Medical record, Respiratory infection, Cryptococcosis, medicine.disease, Respiratory failure, Concomitant, Rheumatoid arthritis, Radiological weapon, Antirheumatic Agents, Female, business
Abstract

Background and objectiveA high frequency of infections complicating rheumatoid arthritis (RA) has been reported due to the immunomodulatory effect of RA or to agents with immunosuppressive effects used in its treatment. We aimed to assess clinical and radiological characteristics of pulmonary cryptococcosis in patients with and without RA.MethodsWe retrospectively reviewed the medical records of 52 patients with pulmonary cryptococcosis and divided them into two groups, those with RA and without RA, and compared clinical characteristics and radiological findings between them.ResultsEleven (21.2%) of the 52 patients had RA. Median follow-up periods were 51.2 (range: 1.1–258.7) months for patients with RA and 19.1 (range: 0.63–246.9) months for patients without RA. Among the patients with RA, 81.8% were women, with a mean age of 68.1 years. Female sex and respiratory comorbidities were significantly more frequent in patients with RA than in patients without RA. Frequencies of concomitant cryptococcal meningitis and respiratory failure were not different between the groups. There were no significant differences in frequency of any radiological findings, locations and number between the two groups. Among patients with RA, all but one responded well to antifungal treatment. During the antifungal treatment course, one (9.1%) patient with RA died of cryptococcosis. Despite continuing antirheumatic drugs, no patients had recurrence of pulmonary cryptococcosis during follow-up.ConclusionOther than some differences in background, there were no clinical, radiological or prognostic differences between the patients with and without RA with pulmonary cryptococcosis. The administration of antirheumatic therapy had no negative effect on the clinical course of antifungal treatment.

Published
2021

17. Pulmonary alveolar proteinosis developing during steroid treatment in a patient with organizing pneumonia in association with atypical chronic myeloid leukemia

Author

Yasuhiko Endo, Yumie Yamanaka, Shota Fujimoto, Kazuyoshi Kuwano, Hanae Miyagawa, Yoshitaka Seki, Akira Kinoshita, Naoaki Watanabe, Chiaki Hosoda, Yusuke Kurita, and Keisuke Saito

Subjects
medicine.medical_specialty, organizing pneumonia, pulmonary alveolar proteinosis, corticosteroid therapy, lcsh:Medicine, Case Report, Case Reports, 030204 cardiovascular system & hematology, 03 medical and health sciences, 0302 clinical medicine, Hematologic disorders, chronic myeloid leukemia, Internal medicine, medicine, In patient, lcsh:R5-920, business.industry, lcsh:R, General Medicine, medicine.disease, Steroid therapy, Corticosteroid therapy, 030220 oncology & carcinogenesis, Atypical chronic myeloid leukemia, Organizing pneumonia, lcsh:Medicine (General), Pulmonary alveolar proteinosis, business
Abstract

Key Clinical Message Organizing pneumonia (OP) and pulmonary alveolar proteinosis (PAP) are rare complications in patients with hematologic disorders. We herein report a case of PAP that developed during steroid treatment for OP in a patient with atypical chronic myeloid leukemia. Physicians should pay close attention to these complications in patients with hematologic malignancies.

Published
2019
Full Text
View/download PDF

18. Japan COVID-19 Task Force: a nation-wide consortium to elucidate host genetics of COVID-19 pandemic in Japan

Author

Shuichi Yoshida, Yoshihiro Hirai, Hiroshi Takahashi, Yoshiyuki Sekikawa, Saeko Takahashi, Yoshitaka Oyamada, Shunsuke Uno, Koutaro Yokote, Kunihiko Takahashi, Shigenari Nukaga, Yoshinao Ono, Shoichiro Ishihara, Nozomu Kimura, Tomohiro Adachi, Shigeki Fujitani, Eri Hagiwara, Motoyuki Suzuki, Tomouki Ogata, Namiki Izumi, Shinji Abe, Etsuko Tagaya, Yoshinori Hasegawa, Yoshimune Miyazaki, Junichi Sasaki, Yoshinori Tanino, Seishi Ogawa, Yuki Togashi, Satoshi Fuke, Yoshiaki Inoue, Hideo Ogata, Masaomi Yamamoto, Hiroshi Saito, Jun Shinozuka, Sho Uchida, Masayoshi Miyawaki, Atsushi Kumanogoh, Koichiro Matsumoto, Yuko Kitagawa, Mayu Endo, Mitsuru Odate, Hiroki Tateno, Fumitake Saito, Mizuki Kuramochi, Shoji Suzuki, Koji Murakami, Kenichi Arakawa, Shozo Yoshida, Hitoshi Sasano, Keigo Kobayashi, Takuro Nii, Takashi Ishiguro, Ryuichi Saito, Yohei Mikami, Takashi Inoue, Haruhiko Kishima, Daisuke Arai, Takao Mochimaru, Minoru Takada, Yuya Ueno, Takehiro Izumo, Reina Hara, Nobuyuki Hizawa, Atsuho Morita, Takanori Hasegawa, Masahiro Seike, Hisako Sageshima, Takeshi Hattori, Shinichi Namba, Shuko Mashimo, Tomoya Tsuchida, Hiromu Tanaka, Naoki Miyazawa, Masatoshi Kawana, Shunichiro Konishi, Takatoshi Enomoto, Takuya Hashino, Hiroki Watanabe, Kentaro Hayashi, Sumito Inoue, Satoshi Hagimoto, Toru Yoshida, Akiko Fujiwara, Masaki Okamoto, Hiroki Kabata, Shuji Tohda, Baku Oyama, Norihiko Takemoto, Nobuyasu Awano, Makoto Hiki, Yasutaka Fukui, Takahiro Fukui, Keisuke Onoi, Yuichiro Yamada, Takayuki Shiroyama, Mayuko Tani, Hiroyuki Muranaka, Kazuhide Ohta, Yoshifumi Kimizuka, Hajime Iwagoe, Yasuko Fuchimo, Hiroki Nakatsumi, Hiroyuki Minemura, Hisatoshi Sugiura, Haruhi Takagi, Hiroyuki Kokuto, Yasuhiro Kimura, Masatoshi Takagaki, Yuki Sato, Masao Hagihara, Junko Kagyo, Yusuke Kawamura, Sayoko Ishihara, Akinori Kimura, Aki Ogawa, Hironori Sagara, Noa Sasa, Masahiro Kanai, Isano Hase, Takenori Okada, Akiyoshi Nakayama, Osamu Narumoto, Norihito Omote, Kazunori Tomono, Toshiro Sato, Hatsuyo Takaoka, Mayumi Takeuchi, Keiko Kan-o, Satoshi Okamori, Yukinori Okada, Yoshito Takeda, Kazuto Ito, Tatsuhiko Naito, Reina Hayashi, Toshikatsu Sado, Kazuya Ichikado, Yasushi Matsushita, Nobuaki Mori, Takashi Nishida, Toshitaka Maeno, Tomomi Takano, Soichiro Ueda, Tomoyasu Nishimura, Masaru Nishitsuji, Ryusuke Anan, Arihiko Kanehiro, Akira Umeda, Syuji Kanayama, Yosuke Omae, Tomoki Nagasaka, Koichi Nishi, Yoshiyuki Ohira, Fumimaro Ito, Toru Tanaka, Kenichiro Takahashi, Hidenori Kanda, Hidenori Inohara, Kaoru Nagata, Kei Nishiyama, Masafumi Watanabe, Katsunori Masaki, Ryuzo Abe, Hirofumi Kamata, Masahiro Harada, Chihiro Tani Sassa, Tomoya Sano, Shoichi Ihara, Tadashi Manabe, Takafumi Ueno, Takahito Fukusumi, Meiko Takahashi, Kyuto Sonehara, Kana Sasaki, Hiroyuki Takoi, Chie Watanabe, Takahiro Tsuburai, Tomonori Sato, Yoichi Kobayashi, Kazuhisa Takahashi, Yasushi Nakano, Kenichi Yamamoto, Takayoshi Hyugaji, Hirohito Sano, Ho Namkoong, Atsushi Sueyoshi, Naoya Ichimura, Yoshiteru Tominaga, Masaru Amishima, Ken Suzuki, Ken Ohta, Shigehiro Hagiwara, Masayuki Kanai, Kota Hoshino, Shuhei Kawabata, Mitsuhiro Yamada, Toshio Naito, Akihiro Ono, Yotaro Takaku, Yoko Sato, Satoru Miyano, Junichi Ochi, Yoshikazu Mutoh, Hiroaki Baba, Yoko Shibata, Tatsuya Yamashita, Yoko Ito, Hiromu Iwamura, Munehisa Fukushima, Saori Amiya, Takayuki Honda, Yuta Kono, Susumu Isogai, Ryuya Edahiro, Makoto Masuda, Hisato Shimada, Hideaki Nagai, Tomoya Baba, Fukuki Saito, Toshihiro Sakurai, Ryota Kikuchi, Yoichiro Noguchi, Tatsuhiko Anzai, Mizuha Hashiguchi, Masamichi Sato, Naoki Hasegawa, Yasunari Miyazaki, Tetsuya Ueda, Yasuhiko Yamano, Shinji Ozaki, Yoshinobu Saito, Takuya Inoue, Sohei Nakayama, Sawako Arai, Yu Kusaka, Miki Kawada, Yuko Kurihara, Daiki Wada, Isamu Kamimaki, Motonao Ishikawa, Sumiko Kohashi, Sae Wada, Kazuma Yagi, Rino Ishihara, Hiroko Okabayashi, Nobuhiro Kodama, Mai Takahashi, Kiyoshi Komuta, Yusuke Chihara, Yoshihiko Nakamura, Akifumi Endo, Shuichiro Matsumoto, Akira Igarashi, Shuhei Yamada, Akiko Yonekawa, Yukiko Nakajima, Sakamoto Koji, Kazue Fujita, Masakiyo Yatomi, Makoto Ishii, Ryuji Koike, Eigo Shimizu, Shigeru Chiba, Satoru Miyawaki, Shunsuke Maeda, Toshio Odani, Hideyasu Sugimoto, Masanori Nishikawa, Yoshinori Yasui, Akira Ando, Takayuki Shibusawa, Nobuharu Ooshima, Toshiyuki Kita, Satoru Fukuyama, Ai Tada, Mariko Terashima, Tadao Nagasaki, Rie Baba, Atsuya Narita, Takanori Ogawa, Tetsuo Shimizu, Ken Ueda, Yuki Haruta, Satoru Hashimoto, Ryohei Suematsu, Ho Lee, Ryosuke Satomi, Hirotaka Eguchi, Kota Ishioka, Ryousuke Aoki, Yusuke Suzuki, Takemasa Matsumoto, Kazunari Sonobe, Hisato Hiranuma, Hirayasu Kai, Kosuke Yoshida, Ayumi Yoshifuji, Takeru Kashiwada, Yuko Harada, Reoto Takei, Aya Wakabayashi, Tomohiro Matsunaga, Haruhiko Hirata, Hiroshi Morisaki, Yoshifumi Uwamino, Yoshihisa Tokunaga, Kazuki Niwa, Hidetoshi Kawashima, Hideki Terai, Kenji Takano, Mumon Takita, Yuko Komase, Masaki Yamasaki, Chiaki Hosoda, Takayuki Ogura, Shun Shibata, Mitsuru Motegi, Takeshi Takahashi, Takehiko Ohba, Shinichi Hayashi, Satoshi Ito, Yu Kasamatsu, Shinnosuke Ikemura, Tetsuya Fukuta, Koichiro Asano, Taka-aki Nakada, Kota Murohashi, Tomoyuki Uchida, Hirotaka Matsuo, Satoko Hanada, Kenta Nishiyama, Minoru Inomata, Nobukazu Fujimoto, Tomoya Tateishi, Mitsuaki Kojima, Kazuto Kato, Kazuhiko Katayama, Yuichi Maeda, Takashi Kagaya, Keiko Wakahara, Takashi Ogura, Yasuhiro Gon, Taku Oshima, Ken Arimura, Shuhei Maruyama, Mari Tone, Ryuichi Sato, Koichi Fukunaga, Hidefumi Koh, Yuichiro Kitagawa, Noboru Takayanagi, Masatoshi Miyazaki, Ichiro Nakachi, Akihiko Kawana, Toshiyuki Hirano, Yohei Funatsu, Yasushi Nakamori, Reiko Sado, Yasuo Shichinohe, Junya Suzuki, Yasunari Kaneyama, Takahito Miyake, Kunihiro Yamagata, Yasuhito Nannya, Shinichi Ogawa, Naoya Hida, Tsuyoshi Oguma, Kazunori Nakamura, Kosaku Nanki, Naozumi Hashimoto, Fumihiko Matsuda, Tomoyuki Kimura, Daiki Morikawa, Yuji Uchimura, Yoshiaki Tanaka, Kazuhisa Yoshiya, Takashige Kuraki, Yoshihiro Eriguchi, Tomohisa Shoko, Tadanaga Shimada, Yuji Hiramatsu, Akihiko Tanaka, Hideya Kitamura, Yutaka Kozu, Ryosuke Arai, Taisuke Isono, Yasushi Makino, Seiya Imoto, Yuichi Adachi, Yuma Matsui, Masato Shinoki, Kazumi Nishio, Keiko Mitamura, Tomonori Imamura, Masanori Azuma, Sonoko Harada, Hiroshi Ono, Kotoe Katayama, Masumi Ai, Keisuke Shinozuka, Reiko Taki, Junichi Maruyama, Takao Imai, Yutaro Kaneko, Kensuke Kanaoka, Sho Ota, Yoji Nagasaki, Toshihiro Kishikawa, Takayuki Niitsu, Hirohisa Horinouchi, Naoyuki Kuse, Tetsuya Shiomi, Jun Nakajima, Katsushi Tokunaga, Norihiro Harada, Keita Masuzawa, Noriyuki Kijima, Takeshi Osawa, Satoru Sakagami, Kazuhiko Fujii, Shotaro Chubachi, Tomoyuki Yoshihara, Yoshimi Noda, Hiroyasu Ishikura, Kiyoshi Koshida, Shin Ohta, Ai Nakamura, Naota Kuwahara, Shinji Ogura, Suguru Ueda, Akihiro Ito, Morio Nakamura, Tohru Takata, Yuya Shirai, Hidenori Takahashi, Eriko Yoshida, Satoru Beppu, Mitsuyoshi Utsugi, Masafumi Shimoda, Masatoshi Shimo, Tomoo Ishii, Takefumi Nikaido, Takanori Asakura, Kazuya Miyagawa, Takanori Kanai, Hiroto Kishi, Akane Kamiya, Genta Nagao, Kodai Kawamura, Ryunosuke Saiki, Takashi Yoshiyama, Hajime Sasano, Kazuyoshi Watanabe, and Yuta Matsubara

Subjects
Genetics, education.field_of_study, Population, Mendelian Randomization Analysis, Genome-wide association study, Odds ratio, Biology, medicine.disease, Obesity, Confidence interval, Minor allele frequency, Pandemic, medicine, education
Abstract

To elucidate the host genetic loci affecting severity of SARS-CoV-2 infection, or Coronavirus disease 2019 (COVID-19), is an emerging issue in the face of the current devastating pandemic. Here, we report a genome-wide association study (GWAS) of COVID-19 in a Japanese population led by the Japan COVID-19 Task Force, as one of the initial discovery GWAS studies performed on a non-European population. Enrolling a total of 2,393 cases and 3,289 controls, we not only replicated previously reported COVID-19 risk variants (e.g., LZTFL1, FOXP4, ABO, and IFNAR2), but also found a variant on 5p35 (rs60200309-A at DOCK2) that was significantly associated with severe COVID-19 in younger (-8 (odds ratio = 2.01, 95% confidence interval = 1.58-2.55). This risk allele was prevalent in East Asians, including Japanese (minor allele frequency [MAF] = 0.097), but rarely found in Europeans. Cross-population Mendelian randomization analysis made a causal inference of a number of complex human traits on COVID-19. In particular, obesity had a significant impact on severe COVID-19. The presence of the population-specific risk allele underscores the need of non-European studies of COVID-19 host genetics.

Published
2021
Full Text
View/download PDF

19. A retrospective analysis of pembrolizumab plus chemotherapy versus pembrolizumab monotherapy for advanced or recurrent non-small cell lung cancer

Author

Tsutomu Yanagisawa, Yuma Matsui, Kazuyoshi Kurashima, Hitomi Nakajima, Noboru Takayanagi, Yotaro Takaku, Chiaki Hosoda, Yoichi Kobayashi, Shun Shibata, Taisuke Isono, Kenji Takano, Takashi Nishida, Eriko Kawate, Naho Kagiyama, and Takashi Ishiguro

Subjects
0301 basic medicine, Pulmonary and Respiratory Medicine, Adult, Male, medicine.medical_specialty, Lung Neoplasms, Combination therapy, medicine.medical_treatment, overall survival, adverse event, immune checkpoint inhibitor, Pembrolizumab, Antibodies, Monoclonal, Humanized, Gastroenterology, law.invention, combination therapy, 03 medical and health sciences, 0302 clinical medicine, Randomized controlled trial, Drug Therapy, law, Internal medicine, Carcinoma, Non-Small-Cell Lung, Antineoplastic Combined Chemotherapy Protocols, medicine, Humans, Adverse effect, RC254-282, Aged, Retrospective Studies, Chemotherapy, business.industry, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Retrospective cohort study, General Medicine, Original Articles, Middle Aged, Survival Analysis, Discontinuation, treatment discontinuation, Clinical trial, 030104 developmental biology, Oncology, 030220 oncology & carcinogenesis, Female, Original Article, business
Abstract

Background Although clinical trials have investigated the addition of pembrolizumab to chemotherapy for non‐small cell lung cancer, none have investigated the addition of chemotherapy to pembrolizumab. Methods We conducted a retrospective study of 71 NSCLC patients including 33 treated with pembrolizumab plus chemotherapy (combination therapy group) and 38 treated with pembrolizumab monotherapy (monotherapy group) from 1 May 2016 to 31 August 2020. Results Eleven of 33 (33.3%) patients in the combination therapy group and 37 of 38 (97.4%) patients in the monotherapy group had programmed cell death ligand‐1 (PD‐L1) tumor proportion score (TPS) ≥50%. Objective response rate (ORR) and median overall survival (OS) were not significantly different between the combination therapy group and monotherapy group (54.5% vs. 47.4, p = 0.637 and 16.6 vs. 27.0 months, p = 0.463). In patients with PD‐L1 TPS ≥50%, ORR and median OS were not different between the combination therapy group and the monotherapy group (63.6% vs. 48.6%, p = 0.499 and not reached vs. 27.0 months, p = 0.976). Thirty‐three (100%) patients experienced adverse events (AEs) in the combination therapy group and 32 (84.2%) in the monotherapy group. Treatment discontinuation at 1 year due to AEs occurred more frequently in the combination therapy group (45.2%) than in the monotherapy group (21.1%). Conclusion There was no significant difference in ORR and OS between the two groups, and treatment discontinuation was more frequent in the combination group. A randomized controlled trial is needed to evaluate the addition of chemotherapy to pembrolizumab for first‐line treatment in patients with PD‐L1 TPS ≥50%., There was no significant difference in clinical response and prognosis between the combination therapy group and the monotherapy group. We think that the higher frequency of treatment discontinuation due to adverse events in the combination therapy group compared to the monotherapy group is one reason why there was no significant difference in prognosis between the two groups.

Published
2021

20. Clinical course and findings of 14 patients with COVID-19 compared with 5 patients with conventional human coronavirus pneumonia

Author

Yoshihiko Shimizu, Eriko Kawate, Yasuhito Kobayashi, Naho Kagiyama, Miyuki Ueda, Takashi Nishida, Kenji Takano, Yotaro Takaku, Yasuhiro Morimoto, Tsutomu Yanagisawa, Ryota Ozawa, Keisuke Kasuga, Yoichi Kobayashi, Taisuke Isono, Naomi Takata, Takashi Ishiguro, Kazuyoshi Kurashima, Noboru Takayanagi, and Chiaki Hosoda

Subjects
Pulmonary and Respiratory Medicine, Wuhan, medicine.medical_specialty, Coronavirus disease 2019 (COVID-19), Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Case Report, Novel coronavirus 2019, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, BALF, bronchoalveolar lavage fluid, medicine, SARS-CoV, severe acute respiratory syndrome coronavirus 2, Respiratory system, COVID-19, coronavirus disease 2019, lcsh:RC705-779, business.industry, SARS-CoV-2, cHCoV, conventional human coronavirus, Clinical course, COVID-19, Lopinavir, lcsh:Diseases of the respiratory system, Pneumonia, medicine.disease, respiratory tract diseases, BVBs, bronchovascular bundles, CT, computed tomography, GGOs, ground-glass opacities, 030228 respiratory system, Respiratory failure, 030220 oncology & carcinogenesis, HFNC, high-flow nasal cannula, CRP, C-reactive protein, Ritonavir, business, medicine.drug
Abstract

Objective To clarify what future problems must be resolved and how clinical findings of SARS-CoV-2 infection differ from those of cHCoV infection. Methods Patients and Methods Clinical characteristics of 14 patients with laboratory-confirmed Coronavirus disease 2019 (COVID-19) and 5 patients with cHCoV pneumonia admitted to our institution and treated up to March 8, 2020, were retrospectively analyzed. Results On admission, 10 patients had pneumonia, 5 of whom had pulmonary shadows detectable only via computed tomography (CT). During hospitalization, another patient with no pulmonary shadows on admission developed pneumonia. In total, 11 (78.6%) of the 14 patients developed pneumonia, indicating its high prevalence in COVID-19. During hospitalization, the patients' symptoms spontaneously relapsed and resolved, and gastrointestinal symptoms were frequently found. C-reactive protein values showed correlation with the patients’ clinical courses. Ritonavir/lopinavir were administered to 5 patients whose respiratory conditions worsened during admission, all of whom improved. However, the pneumonia in the 6 other patients improved without antivirals. None of the 14 patients died, whereas 5 other patients with cHCoV pneumonia were in respiratory failure on admission, and one patient (20%) died. Conclusion Both SARS-CoV-2 and cHCoV can cause severe pneumonia. Problems for future resolution include whether antiviral agents administered in cases of mild or moderate severity can reduce the number of severe cases, and whether antivirals administered in severe cases can reduce mortality.

Published
2020

21. IgG antibody seroconversion and the clinical progression of COVID-19 pneumonia: A retrospective, cohort study

Author

Yuma Matsui, Yotaro Takaku, Kazuyoshi Kurashima, Shun Shibata, Noboru Takayanagi, Yoichi Kobayashi, Chiaki Hosoda, Taisuke Isono, Kenji Takano, Eriko Kawate, Naho Kagiyama, Takashi Nishida, Takashi Ishiguro, Tsutomu Yanagisawa, and Hiromi Nakajima

Subjects
medicine.medical_specialty, biology, business.industry, Retrospective cohort study, medicine.disease, medicine.disease_cause, Gastroenterology, Hypoxemia, Pneumonia, Respiratory failure, Viral pneumonia, Internal medicine, medicine, biology.protein, Seroconversion, medicine.symptom, Antibody, business, Coronavirus
Abstract

SummaryBackgroundCoronavirus Disease 2019 (COVID-19) causes severe acute respiratory failure. Antibody-dependent enhancement (ADE) is known as the mechanism for severe forms of other coronavirus diseases. The clinical progression of COVID-19 before and after IgG antibody seroconversion was investigated.MethodsFifty-three patients with reverse transcriptase PCR (RT-PCT)-confirmed COVID-19 viral pneumonia with or without respiratory failure were retrospectively investigated. The timing of the first IgG antibody against SARS-CoV-2-positive date, as well as changes of C-reactive protein (CRP) as an inflammatory marker and blood lymphocyte numbers, was assessed using serial preserved blood samples.FindingsTen patients recovered without oxygen therapy (mild/moderate group), 32 patients had hypoxemia and recovered with antiviral drugs (severe/non-ICU group), and 11 patients had severe respiratory failure and were treated in the ICU (6 of them died; critical/ICU group). The first IgG-positive date (day 0) was observed from 5 to 18 days from the onset of disease. At day 0, a CRP peak was observed in the severe and critical groups, whereas there was no synchronized CRP peak on day 0 in the mild/moderate group. In the severe/non-ICU group, the blood lymphocyte number increased (P=0.0007) and CRP decreased (P=0.0007) after day 0, whereas CRP did not decrease and the blood lymphocyte number further decreased (P=0.0370) in the critical/ICU group.InterpretationThe respiratory failure due to COVID-19 viral pneumonia observed in week 2 may be related to an antibody-related mechanism rather than uncontrolled viral replication. In the critical form of COVID-19, inflammation was sustained after IgG seroconversion.Fundingnone

Published
2020
Full Text
View/download PDF

22. Remitting Seronegative Symmetrical Synovitis with Pitting Edema Syndrome Complicated with Organizing Pneumonia

Author

Takashi Ishiguro, Noboru Takayanagi, Chiaki Hosoda, Yoshihiko Shimizu, Taisuke Isono, Atsuki Furube, and Yasuhiro Morimoto

Subjects
Vascular Endothelial Growth Factor A, Male, medicine.medical_specialty, Remitting seronegative symmetrical synovitis with pitting edema, Prednisolone, RS3PE, Case Report, complication, 030204 cardiovascular system & hematology, 03 medical and health sciences, Idiopathic pulmonary fibrosis, 0302 clinical medicine, Internal Medicine, medicine, pulmonary involvement, Edema, Humans, Synovitis, MMP-3, vascular endothelial growth factor, business.industry, General Medicine, Pneumonia, Syndrome, Middle Aged, remitting seronegative symmetrical synovitis with pitting edema, idiopathic pulmonary fibrosis, medicine.disease, Dermatology, VEGF, Editorial, matrix metalloproteinase 3, remitting seronegative symmetrical synovitis with pitting edema syndrome, 030211 gastroenterology & hepatology, Organizing pneumonia, medicine.symptom, business, Complication, medicine.drug
Abstract

We herein report a 62-year-old man with idiopathic pulmonary fibrosis who developed remitting seronegative symmetrical synovitis with pitting edema (RS3PE) syndrome during follow-up. Pulmonary infiltrations were detected concomitantly with the development of RS3PE syndrome, and prednisolone improved both the pulmonary and extrapulmonary lesions. Recognizing the pulmonary manifestations of RS3PE syndrome is necessary to provide an appropriate diagnosis and disease management.

Published
2020

23. Mycobacterium genavense Infection Presenting as an Endobronchial Polyp and Upper Lobe Atelectasis

Author

Yoshihiko Shimizu, Noboru Takayanagi, Hirokazu Kanegane, Chiaki Hosoda, and Takashi Ishiguro

Subjects
Pulmonary and Respiratory Medicine, Pathology, medicine.medical_specialty, biology, business.industry, Mycobacterium genavense, Atelectasis, Critical Care and Intensive Care Medicine, medicine.disease, biology.organism_classification, Lobe, medicine.anatomical_structure, Medicine, business
Published
2020
Full Text
View/download PDF

24. Spontaneous regression of primary endobronchial extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue

Author

Takashi Ishiguro, Nobumasa Takahashi, Nobufumi Kamiishi, Yoshihiko Shimizu, Noboru Takayanagi, and Chiaki Hosoda

Subjects
Pulmonary and Respiratory Medicine, Pathology, medicine.medical_specialty, Marginal zone lymphoma, Article, 03 medical and health sciences, 0302 clinical medicine, immune system diseases, hemic and lymphatic diseases, medicine, lcsh:RC705-779, Spontaneous regression, Bronchus, business.industry, food and beverages, MALT lymphoma, lcsh:Diseases of the respiratory system, medicine.disease, digestive system diseases, Lymphatic system, medicine.anatomical_structure, 030228 respiratory system, 030220 oncology & carcinogenesis, Endobronchial extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue, business, Mucosa-associated lymphoid tissue, Rare disease
Abstract

Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) of pulmonary origin is a relatively rare disease. In particular, reports of MALT lymphoma occurring and localized in the trachea or bronchus have been limited. Pulmonary MALT lymphoma has been reported to demonstrate spontaneous regression, whereas there is only one reported case of spontaneous regression of primary endobronchial MALT lymphoma. We herein report the case of a 70-year-old man with primary endobronchial MALT lymphoma who showed spontaneous regression with an interest of endobronchial findings. Keywords: Endobronchial extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue, Spontaneous regression, Bronchus

Published
2019

27. Clinical features of usual interstitial pneumonia with anti-neutrophil cytoplasmic antibody in comparison with idiopathic pulmonary fibrosis

Author

Hiroyuki Ito, Chiaki Hosoda, Koji Okudela, Hideya Kitamura, Norikazu Matsuo, Takashi Ogura, Eri Hagiwara, Tae Iwasawa, Tomohisa Baba, and Tamiko Takemura

Subjects
Pulmonary and Respiratory Medicine, Pathology, medicine.medical_specialty, medicine.diagnostic_test, business.industry, Lung biopsy, respiratory system, medicine.disease, respiratory tract diseases, 03 medical and health sciences, Idiopathic pulmonary fibrosis, 0302 clinical medicine, Bronchoalveolar lavage, 030228 respiratory system, immune system diseases, Usual interstitial pneumonia, Pulmonary fibrosis, medicine, cardiovascular diseases, 030212 general & internal medicine, Honeycombing, skin and connective tissue diseases, Microscopic polyangiitis, business, Anti-neutrophil cytoplasmic antibody
Abstract

Background and objective Myeloperoxidase anti-neutrophil cytoplasmic antibody (MPO-ANCA) is occasionally positive in patients with usual interstitial pneumonia (UIP). However, the differences from idiopathic pulmonary fibrosis (IPF/UIP) have not been well documented. We aimed to clarify the clinical, radiological and pathological features of UIP associated with MPO-ANCA (ANCA/UIP). Methods We retrospectively reviewed the medical records of 12 consecutive ANCA/UIP patients not manifesting microscopic polyangiitis and 108 IPF/UIP patients with no autoantibodies, both diagnosed by surgical lung biopsy. Results There was no significant difference in clinical background, laboratory results and pulmonary function tests between ANCA/UIP patients and IPF/UIP patients except for the percentage of bronchoalveolar lavage neutrophils. HRCT showed subpleural reticulation in both groups. Increased attenuation around honeycombing and cysts was significantly observed in ANCA/UIP. Pathologically, ANCA/UIP had more prominent inflammatory cell infiltration, lymphoid follicles with germinal centres and cellular bronchiolitis. During the disease course, three of 12 patients (25%) developed microscopic polyangiitis. Immunosuppressive treatment tended to be more effective in ANCA/UIP patients, and the survival time in ANCA/UIP patients tended to be longer than those with IPF/UIP. Conclusion ANCA/UIP may be distinguishable from IPF/UIP with a combination of HRCT findings of increased attenuation around honeycombing and cysts and some of the characteristic pathological findings. In contrast to IPF/UIP, immunosuppressive treatment could be a therapeutic option for ANCA/UIP.

Published
2016
Full Text
View/download PDF

29. Promising Effect of Crizotinib on Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small Cell Lung Cancer in an Elderly Patient with a Poor Performance Status: A Case Report and Literature Review

Author

Norikazu Matsuo, Terufumi Kato, Chiaki Hosoda, Shigeaki Umeda, Tae Iwasawa, Akimasa Sekine, Takashi Ogura, Tomohisa Baba, Hiroyuki Ito, and Koji Okudela

Subjects
Male, Oncology, medicine.medical_specialty, Lung Neoplasms, Pyridines, Antineoplastic Agents, 03 medical and health sciences, Fatal Outcome, 0302 clinical medicine, Crizotinib, Carcinoma, Non-Small-Cell Lung, hemic and lymphatic diseases, Internal medicine, Biomarkers, Tumor, Internal Medicine, medicine, Carcinoma, Humans, Anaplastic lymphoma kinase, Anaplastic Lymphoma Kinase, Poor performance status, Molecular Targeted Therapy, 030212 general & internal medicine, Lung cancer, Adverse effect, Protein Kinase Inhibitors, Aged, 80 and over, Performance status, Brain Neoplasms, business.industry, Receptor Protein-Tyrosine Kinases, General Medicine, Protein-Tyrosine Kinases, medicine.disease, respiratory tract diseases, 030220 oncology & carcinogenesis, Pyrazoles, Non small cell, business, medicine.drug
Abstract

Crizotinib is highly effective for anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC). However, it remains unclear whether crizotinib has a beneficial effect on elderly patients with ALK-positive NSCLC with a poor performance status (PS). We herein present the case of an 85-year-old man with stage IV ALK-positive NSCLC, whose PS score was 4 due to pericardial and pleural effusions. After initiating crizotinib therapy, a drastic response was observed and the PS score improved to 0. Adverse effects were manageable. Our results indicate that crizotinib could be an important choice when treating elderly patients with ALK-positive NSCLC with poor PS.

Published
2016
Full Text
View/download PDF

30. Clinical features of usual interstitial pneumonia with anti-neutrophil cytoplasmic antibody in comparison with idiopathic pulmonary fibrosis

Author

Chiaki, Hosoda, Tomohisa, Baba, Eri, Hagiwara, Hiroyuki, Ito, Norikazu, Matsuo, Hideya, Kitamura, Tae, Iwasawa, Koji, Okudela, Tamiko, Takemura, and Takashi, Ogura

Subjects
Adult, Male, Biopsy, Pulmonary Fibrosis, Middle Aged, Survival Analysis, Idiopathic Pulmonary Fibrosis, Antibodies, Antineutrophil Cytoplasmic, Respiratory Function Tests, Japan, Humans, Female, Tomography, X-Ray Computed, Lung, Immunosuppressive Agents, Aged, Peroxidase, Retrospective Studies
Abstract

Myeloperoxidase anti-neutrophil cytoplasmic antibody (MPO-ANCA) is occasionally positive in patients with usual interstitial pneumonia (UIP). However, the differences from idiopathic pulmonary fibrosis (IPF/UIP) have not been well documented. We aimed to clarify the clinical, radiological and pathological features of UIP associated with MPO-ANCA (ANCA/UIP).We retrospectively reviewed the medical records of 12 consecutive ANCA/UIP patients not manifesting microscopic polyangiitis and 108 IPF/UIP patients with no autoantibodies, both diagnosed by surgical lung biopsy.There was no significant difference in clinical background, laboratory results and pulmonary function tests between ANCA/UIP patients and IPF/UIP patients except for the percentage of bronchoalveolar lavage neutrophils. HRCT showed subpleural reticulation in both groups. Increased attenuation around honeycombing and cysts was significantly observed in ANCA/UIP. Pathologically, ANCA/UIP had more prominent inflammatory cell infiltration, lymphoid follicles with germinal centres and cellular bronchiolitis. During the disease course, three of 12 patients (25%) developed microscopic polyangiitis. Immunosuppressive treatment tended to be more effective in ANCA/UIP patients, and the survival time in ANCA/UIP patients tended to be longer than those with IPF/UIP.ANCA/UIP may be distinguishable from IPF/UIP with a combination of HRCT findings of increased attenuation around honeycombing and cysts and some of the characteristic pathological findings. In contrast to IPF/UIP, immunosuppressive treatment could be a therapeutic option for ANCA/UIP.

Published
2015

31. [Clinical characteristics of pulmonary Mycobacterium avium complex infection complicated with lung cancer]

Author

Chiaki, Hosoda, Eri, Hagiwara, Takeshi, Shinohara, Tomohisa, Baba, Ryuichi, Nishihira, Shigeru, Komatsu, and Takashi, Ogura

Subjects
Aged, 80 and over, Male, Lung Neoplasms, Humans, Female, Middle Aged, Tuberculosis, Pulmonary, Aged, Mycobacterium avium, Retrospective Studies
Abstract

The coexistence of lung cancer and pulmonary Mycobacterium avium complex (MAC) infection has not been well reported. This study illustrated the clinical characteristics of pulmonary MAC infections complicated with lung cancer.We conducted a retrospective analysis of the clinical characteristics of patients with pulmonary MAC infections complicated with newly diagnosed lung cancer between 2006 and 2012.Of 530 patients with pulmonary MAC infections, 13 (2.4%) were complicated with lung cancer. Six men and 7 women with a mean age of 73 years were also diagnosed with cancer, and 5 had a smoking history. Six patients were diagnosed concurrently, and 7 patients were diagnosed with pulmonary MAC infections prior to being diagnosed with cancer. Histological examination revealed adenocarcinoma, small cell carcinoma, and other cancer types in 9, 2, and 2 patients, respectively. Eleven of 13 patients had cancers of stages I-IIIA, and 10 underwent cancer resection. Analysis of the anatomical relationship between lung cancer and MAC revealed that both diseases were present in the same lobe in 10 patients. The disease extent was within one-third of a single lung field in 9 patients. Anti-MAC treatment was initiated in 7 patients, but was discontinued in 2 patients owing to side effects. Six patients did not receive anti-MAC treatment.In this study, lung cancer was frequent among patients with pulmonary MAC infections, and both diseases tended to be in the early stages. Physicians should consider coexisting lung cancer when managing MAC infections.

Published
2014

32. Infection Presenting as an Endobronchial Polyp and Upper Lobe Atelectasis.

Author

Chiaki Hosoda, Takashi Ishiguro, Yoshihiko Shimizu, Hirokazu Kanegane, Noboru Takayanagi, Hosoda, Chiaki, Ishiguro, Takashi, Shimizu, Yoshihiko, Kanegane, Hirokazu, and Takayanagi, Noboru

Subjects
POLYMYALGIA rheumatica, ATELECTASIS, CHRONIC granulomatous disease, MYCOBACTERIAL diseases, BIOPSY
Abstract

The article presents a case study of a 73-year-old man with a history of polymyalgia rheumatica, hilar lymphadenopathy, and right upper lobe atelectasis. Topics include that the examination through biopsy showed chronic granulomatous inflammation; and the confirmation of Mycobacterium genavense Infection.

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results